Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

Item
http://www.wikidata.org/entity/Q27030560
Proximity ligation assay evaluates IDH1R132H presentation in gliomasProstate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine DesignActivation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State.The effect of helper epitopes and cellular localization of an antigen on the outcome of gene gun DNA immunization.Mannan Derivatives Instruct Dendritic Cells to Induce Th1/Th2 Cells Polarization via Differential Mitogen-Activated Protein Kinase Activation.Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.CD74 and intratumoral immune response in breast cancer.Current status and future directions of cancer immunotherapy.
P2860

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

Item
http://www.wikidata.org/entity/Q27030560
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@ast
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@en
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@nl
type
label
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@ast
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@en
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@nl
prefLabel
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@ast
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@en
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@nl
P1433
P1476
P2093
P275
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Optimal MHC-II-restricted tumo ...... lopment of anti-tumor vaccines
@en
P2093
P275
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932